Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors.

The company has developed pipelines of highly promising novel drugs that aim to overcome the current limitations of cancer immunotherapy. For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.